A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around the world has found. Results of the trial are being published by the New England Journal of Medicine, together with an accompanying editorial.
from Medical Xpress - latest medical and health news stories https://ift.tt/4D7NCtb
